- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: The future of antibody therapy in Chronic Lymphocytic Leukemia. (Pubmed Central) - Jan 27, 2022 In this review, we highlight the important role that anti-CD20 antibody therapy has had in the field of CLL, both when used with chemotherapy and in combination with targeted therapy, as well as the current studies that are further exploring this treatment paradigm in the modern era. While anti-CD20 antibodies have played a pivotal role in the treatment of CLL, additional studies will be required to determine the optimal application of these therapies in combination with targeted therapy.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System (clinicaltrials.gov) - Jan 27, 2022 P1, N=12, Not yet recruiting,
- |||||||||| Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma, Otsuka, Gazyva (obinutuzumab) / Roche, Biogen
Review, Journal: Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses. (Pubmed Central) - Jan 26, 2022 This review aggregates evidence of therapy for clinicians and sheds light on comparative efficacies of alternative LN treatments. As more promising agents are entering the market, such as voclosporin, belimumab, and obinutuzumab, LN management might undergo significant changes during the next years.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 24, 2022 P2, N=81, Active, not recruiting, As more promising agents are entering the market, such as voclosporin, belimumab, and obinutuzumab, LN management might undergo significant changes during the next years. Recruiting --> Active, not recruiting
- |||||||||| Trial completion date, Trial primary completion date, Combination therapy: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Jan 24, 2022
P1, N=32, Recruiting, Recruiting --> Active, not recruiting Trial completion date: May 2027 --> Sep 2027 | Trial primary completion date: May 2023 --> Apr 2022
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal, IO biomarker: Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction. (Pubmed Central) - Jan 21, 2022 These results reveal EGR-1 as a key mediator of the direct cytotoxic activity of anti-CD20 mAbs and provide a rationale to evaluate EGR-1 expression as a new biomarker to predict response to anti-CD20 treatment. In addition, our findings show that calcium influx is required for anti-CD20-mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20 based immunotherapy.
- |||||||||| Vistide (cidofovir) / Gilead
BK POLYOMAVIRUS NEPHRITIS IN A LOW RISK, NATIVE KIDNEY (Poster Area (Virtual)) - Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_775; This case highlights that BK nephropathy may develop in the native kidney other than HSCT. Chronic lymphopenia and hypogammaglobinemia likely predisposed our patient despite his ongoing infusion of IVIG.
- |||||||||| lenalidomide / Generic mfg.
Review, Journal: Early Progressing Follicular Lymphoma. (Pubmed Central) - Jan 20, 2022 Ongoing trials seek to identify the optimal management of these patients, and data from bispecific antibodies and CAR T cell therapies is forthcoming. With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Trial termination, Trial primary completion date: VENOBI-CNS: Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (clinicaltrials.gov) - Jan 19, 2022 P1, N=4, Terminated, With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes. Trial completion date: Mar 2024 --> Nov 2021 | Suspended --> Terminated | Trial primary completion date: Jul 2023 --> Nov 2021; low recruitment
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Calquence (acalabrutinib) / AstraZeneca
New P3 trial: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL (clinicaltrials.gov) - Jan 19, 2022 P3, N=650, Not yet recruiting,
- |||||||||| Clinical, P2 data, Journal, Residual disease, Minimal residual disease: Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. (Pubmed Central) - Jan 18, 2022
P2 BOVen was well tolerated and met its primary endpoint, with 33 (89%) of 37 previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma reaching undetectable MRD in both peripheral blood and bone marrow despite a median treatment duration of only 10 months, owing to our undetectable MRD-driven treatment discontinuation design. These data support further evaluation of the BOVen regimen in chronic lymphocytic leukaemia and small lymphocytic lymphoma with treatment duration guided by early MRD response kinetics.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Combination therapy: PrE0403: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (clinicaltrials.gov) - Jan 12, 2022 P2, N=56, Active, not recruiting, N=60 --> 1 | Recruiting --> Terminated; Very slow recruitment due to lack of relapse in the observed group of patients Trial completion date: Jan 2024 --> Jun 2023
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
Journal: Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. (Pubmed Central) - Jan 11, 2022 The combination of an easily expandable CIK cell effector population with a mAb already in clinical use establishes a tumor antigen-specific redirection strategy that can be rapidly translated into clinical practice, providing an effective therapeutic alternative for B-cell malignancies without any need for genetic modifications. Additionally, the approach can be potentially applied to an extremely vast array of different tumors by simply substituting the targeting mAb.
- |||||||||| Trial completion date, Trial primary completion date, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 11, 2022
P1, N=133, Active, not recruiting, Additionally, the approach can be potentially applied to an extremely vast array of different tumors by simply substituting the targeting mAb. Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Dec 2021 --> Aug 2022
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial completion, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 11, 2022 P1, N=114, Completed, Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Dec 2021 --> Aug 2022 Active, not recruiting --> Completed
- |||||||||| FT516 / Fate Therap
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: FT516-101: FT516 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) - Jan 11, 2022 P1, N=234, Recruiting, Active, not recruiting --> Completed N=72 --> 234 | Trial completion date: May 2026 --> May 2039 | Trial primary completion date: Jul 2021 --> May 2024
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: CRISTALLO: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (clinicaltrials.gov) - Jan 11, 2022 P3, N=165, Recruiting, N=72 --> 234 | Trial completion date: May 2026 --> May 2039 | Trial primary completion date: Jul 2021 --> May 2024 Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Apr 2023 --> Aug 2023
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
Retrospective data, Review, Journal: Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. (Pubmed Central) - Jan 5, 2022 Trial completion date: Jul 2021 --> Nov 2021 This systematic review and network meta-analysis indicated that upfront AO prolongs PFS in comparison with IO and VO, whereas no differences are observed between IO, VO, and single-agent A. Hopefully, ongoing studies will further delineate the position of different TAs in chronic lymphocytic leukemia therapy based on effectiveness, availability, safety, cost, and treatment objectives.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
Journal, IO biomarker: Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. (Pubmed Central) - Jan 4, 2022 Moreover, the optimal sequencing of targeted therapies remains to be determined. A particular challenge of the next few years will be to identify alternative therapies for patients with BTK and BCL2 inhibitor double-refractory disease.
- |||||||||| rhIL-15 / National Cancer Institute
Trial completion, Trial completion date, Trial primary completion date: Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia (clinicaltrials.gov) - Jan 4, 2022 P1, N=1, Completed, A particular challenge of the next few years will be to identify alternative therapies for patients with BTK and BCL2 inhibitor double-refractory disease. Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2021 | Trial primary completion date: Jun 2023 --> Dec 2021
- |||||||||| Columvi (glofitamab) / Roche, Lunsumio (mosunetuzumab) / Roche, Biogen
Enrollment open, CAR T-Cell Therapy: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov) - Jan 4, 2022 P2, N=42, Recruiting, Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2021 | Trial primary completion date: Jun 2023 --> Dec 2021 Not yet recruiting --> Recruiting
|